Dechra Pharmaceuticals plc (LON:DPH) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2,821.49 and traded as high as $2,866.00. Dechra Pharmaceuticals shares last traded at $2,800.00, with a volume of 136,182 shares trading hands.
A number of equities research analysts recently weighed in on DPH shares. Jefferies Financial Group cut Dechra Pharmaceuticals to a “hold” rating and dropped their price target for the company from GBX 3,090 ($40.65) to GBX 2,930 ($38.54) in a research note on Tuesday, January 21st. JPMorgan Chase & Co. reduced their price objective on shares of Dechra Pharmaceuticals from GBX 3,500 ($46.04) to GBX 3,200 ($42.09) and set an “overweight” rating for the company in a research report on Monday, January 6th. Finally, HSBC upped their price objective on shares of Dechra Pharmaceuticals from GBX 2,915 ($38.35) to GBX 2,950 ($38.81) and gave the company a “hold” rating in a report on Monday, December 2nd.
The firm has a market cap of $2.88 billion and a P/E ratio of 93.02. The firm’s fifty day moving average is GBX 2,907.16 and its 200 day moving average is GBX 2,820.77. The company has a debt-to-equity ratio of 60.52, a quick ratio of 1.56 and a current ratio of 2.47.
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
Recommended Story: What is the market perform rating?
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.